APA (7th ed.) Citation

M, W., S, O., D, J., H, B., A, B., F, B., . . . C, R. (2026). MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: A phase 1 trial. Nature medicine. https://doi.org/10.1038/s41591-026-04455-x

Chicago Style (17th ed.) Citation

M, Wermke, et al. "MAGE-A4/MAGE-A8-targeted TCR-based Bispecific T Cell Engager in Recurrent And/or Refractory Solid Tumors: A Phase 1 Trial." Nature Medicine 2026. https://doi.org/10.1038/s41591-026-04455-x.

MLA (9th ed.) Citation

M, Wermke, et al. "MAGE-A4/MAGE-A8-targeted TCR-based Bispecific T Cell Engager in Recurrent And/or Refractory Solid Tumors: A Phase 1 Trial." Nature Medicine, 2026, https://doi.org/10.1038/s41591-026-04455-x.